D. Planchard

D. de Ruysscher, D. Planchard, J. Adam, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Focus on Recommendations for the Management of Non-small Cell Lung Cancer

D. Planchard, T. de Baère, J. Adam, 2019, CardioVascular and Interventional Radiology.

CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

D. Planchard, P. Validire, J. Adam, 2020, Cell reports. Medicine.

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

P. Jänne, M. Ranson, Y. Ohe, 2016, Cancer Chemotherapy and Pharmacology.

Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression.

D. Planchard, C. Caramella, L. Lacroix, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

N. Girard, D. Planchard, P. Dubray-Longeras, 2021, Targeted Oncology.

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

P. Jänne, D. Planchard, S. Kim, 2021, ESMO open.

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

A. Geraud, D. Planchard, J. Delahousse, 2020, Cancers.

A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.

L. Mir, T. B. Bakker Schut, D. Planchard, 2017, Cancer research.

Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

D. Planchard, J. Soria, P. Vielh, 2011, British Journal of Cancer.

[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment].

D. Planchard, B. Besse, J. Hadoux, 2011, Presse medicale.

Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.

D. Planchard, G. Le Teuff, J. Soria, 2014, Lung cancer.

Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

A. Fourcade, É. Minvielle, D. Planchard, 2022, Nature Medicine.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Gregory Riely, D. Planchard, M. Hellmann, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer

D. Planchard, N. Chaput, J. Remon, 2016, Current opinion in oncology.

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).

P. Jänne, M. Ranson, M. Ahn, 2014 .

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data

C. Comtat, E. Fadel, D. Planchard, 2020, EJNMMI Research.

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.

D. Planchard, P. Cascetta, M. Riudavets, 2022, Lung cancer.

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease

D. Planchard, O. Mir, M. Ducreux, 2022, Cancers.

Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.

D. Planchard, L. Lacroix, B. Besse, 2022, Clinical lung cancer.

MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).

P. Jänne, N. Hanna, E. Smit, 2013 .

Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).

H. Groen, J. Rigas, D. Planchard, 2015 .

MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study

M. Socinski, G. Scagliotti, N. Pavlakis, 2017 .

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

M. Zauderer, R. Cameron, D. Planchard, 2018 .

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

D. Planchard, M. Ducreux, E. Baudin, 2013, Endocrine-related cancer.

Intervention in gastro-enteropancreatic neuroendocrine tumours.

D. Planchard, M. Ducreux, E. Baudin, 2012, Best practice & research. Clinical gastroenterology.

Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study

A. Chapelier, E. Fadel, M. Papotti, 2017, Neuroendocrinology.

Abstract 3192: Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples

N. Rosenfeld, D. Planchard, V. Plagnol, 2016 .

Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.

N. Girard, F. Bertucci, P. Gestraud, 2022, Lung cancer.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

J. Pignon, D. Planchard, N. Chaput, 2017, Lung cancer.

Targeting ALK-rearranged non-small-cell lung cancer: an update.

D. Planchard, I. Sullivan, 2017, Future oncology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Have We Really MET a New Target?

D. Planchard, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.

D. Planchard, A. Adjei, A. Desai, 2021, Lung cancer.

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

S. Cedrés, D. Planchard, K. Yoh, 2020, Investigational New Drugs.

Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers

M. Dimopoulos, D. Planchard, P. Validire, 2008, Clinical Cancer Research.

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

M. Socinski, E. Smit, Gregory Riely, 2014 .

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

H. Groen, D. Planchard, J. Wolf, 2022, JTO Clinical and Research Reports.

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

D. Planchard, B. Besse, A. Levy, 2021, Cancer management and research.

Interventional radiology: role in the treatment of liver metastases from GEP-NETs

D. Planchard, T. de Baère, M. Ducreux, 2015 .

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

D. Planchard, J. Adam, C. Caramella, 2019, European Journal of Nuclear Medicine and Molecular Imaging.

AZD3759 for CNS metastases in EGFR-mutant lung cancer.

D. Planchard, 2017, The Lancet. Respiratory medicine.

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.

M. Zauderer, R. Cameron, D. Planchard, 2022, The Lancet. Oncology.

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

E. Felip, D. Planchard, L. Paz-Ares, 2016 .

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, T. Mok, K. Kerr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of current immune checkpoint inhibitors in non-small cell lung cancer

D. Planchard, P. Abdayem, 2021, Expert opinion on drug safety.

Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

P. V. Van Schil, T. Mok, K. Kerr, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.

D. Planchard, N. Chaput, E. Lanoy, 2016, Journal of Crohn's & colitis.

Three-year overall survival update from the PACIFIC trial.

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

N. Girard, A. Stenzinger, C. Swanton, 2019 .

Deciphering the metabolism/vascularization regional interlinks in primary NSCLC First-in human simultaneous full kinetic 18F-FDG PET-MRI voxel-wise analysis

C. Comtat, E. Fadel, D. Planchard, 2020 .

F-FDG PET and DCE kinetic modeling and their interlinks in primary NSCLC: First-in human simultaneous [18F]FDG PET-MRI voxel-wise correlation analysis Running title: dynamic [18F]FDG PET/DCE-MRI interlinks in NSCLC

C. Comtat, E. Fadel, D. Planchard, 2020 .

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2021 .

Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

D. Planchard, J. Adam, Gwendoline Gros, 2021, Nature Communications.

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

A. Drilon, S. Gettinger, L. Crinò, 2019, The Lancet. Oncology.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

E. Felip, D. Planchard, N. Chaput, 2018, JAMA oncology.

Durvalumab in non-small-cell lung cancer patients: current developments.

D. Planchard, L. Mezquita, 2018, Future oncology.

Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants

S. Cairo, D. Planchard, J. Scoazec, 2022, JCI insight.

C. Swanton, U. Dafni, D. de Ruysscher, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

P. Jänne, E. Smit, E. Felip, 2021, The New England journal of medicine.

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

P. Jänne, E. Smit, E. Felip, 2020 .

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

H. Groen, M. Socinski, E. Smit, 2017 .

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

D. Planchard, C. Faivre-Finn, S. Senan, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of COVID-19 on healthcare organisation and cancer outcomes

D. Planchard, M. Ducreux, S. Michiels, 2021, European Journal of Cancer.

CMAR_A_292730 2805..2810

D. Planchard, B. Besse, A. Levy, 2021 .

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer

Y. Ohe, D. Planchard, S. Ramalingam, 2019, Clinical Cancer Research.

P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

D. Planchard, J. Adam, J. Soria, 2017 .

Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.

D. Planchard, N. Chaput, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of Oncology.

1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)

D. Planchard, J. Soria, G. Viscardi, 2020 .

Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.

D. Planchard, C. Boutros, J. Remon, 2016, Lung cancer.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2018, The New England journal of medicine.

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.

D. Planchard, C. Faivre-Finn, S. Senan, 2021, Future oncology.

Autoimmune protein S activity deficiency following a Q fever

D. Planchard, A. Turhan, G. Agius, 2007, Thrombosis and Haemostasis.

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

D. Planchard, J. Soria, T. Yokoi, 2016, Clinical lung cancer.

D. Planchard, E. Deutsch, B. Besse, 2022, Frontiers in Immunology.

Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay.

D. Planchard, V. Plagnol, P. Saintigny, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

D. Planchard, F. Guisier, M. Wislez, 2022, Cancers.

The role of brigatinib in crizotinib-resistant non-small cell lung cancer

D. Planchard, L. Mezquita, 2018, Cancer management and research.

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

D. Planchard, I. Sullivan, 2016, Therapeutic advances in medical oncology.

MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer.

D. Planchard, J. Soria, R. Pirker, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)

D. Planchard, J. Soria, S. Koscielny, 2017 .

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

S. Peters, E. Felip, F. de Marinis, 2020, ESMO Open.

Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report.

D. Planchard, J. Adam, C. Caramella, 2020, Clinical lung cancer.

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score

D. Planchard, B. Besse, L. Mezquita, 2022, Cancers.

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.

D. Planchard, A. Italiano, J. Soria, 2022, JCO precision oncology.

Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients.

D. Planchard, C. Caramella, B. Besse, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.

D. Planchard, J. Adam, J. Soria, 2020, JCO precision oncology.

Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).

D. Planchard, J. Soria, J. Mazières, 2019, Journal of Clinical Oncology.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases

D. Planchard, J. Adam, C. Caramella, 2019, Journal of Thoracic Oncology.

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

D. Planchard, A. Azarine, V. Thomas de Montpréville, 2022, JTO clinical and research reports.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Differential expression of biomarkers in men and women.

D. Planchard, J. Soria, Y. Loriot, 2009, Seminars in oncology.

Bevacizumab in non-small-cell lung cancer: a review

D. Planchard, 2011, Expert review of anticancer therapy.

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

C. Rudin, M. Socinski, Gregory Riely, 2013 .

Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms.

L. Spaggiari, F. de Marinis, D. Planchard, 2020, Lung cancer.

Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors.

D. Planchard, E. Baudin, V. Hervieu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, The New England journal of medicine.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, E. Smit, T. Mok, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, T. Mok, K. Kerr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

N. Segata, E. Le Chatelier, N. Pons, 2022, Nature Medicine.

Small cell lung cancer: a slightly less orphan disease after immunotherapy.

G. Giaccone, D. Planchard, J. Soria, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

C. Lázaro, G. Capellá, D. Planchard, 2020 .

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.

D. Planchard, S. Michiels, F. André, 2020, European journal of cancer.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].

S. Lantuejoul, D. Planchard, J. Adam, 2016, Annales de pathologie.

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

D. Planchard, I. Sullivan, P. Abdayem, 2021, ESMO open.

Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

N. Girard, K. Samitas, D. Planchard, 2022, JTO clinical and research reports.

Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.

J. Pignon, D. Planchard, J. Soria, 2012, Lung cancer.

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

J. Blay, D. Planchard, J. Mazières, 2020, Clinical Cancer Research.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Olivier Lantz, Laurence Zitvogel, Clotilde Théry, 2015, Oncoimmunology.

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

G. Rossi, D. Planchard, M. Tiseo, 2018, Cancer treatment reviews.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.

J. Pignon, D. Planchard, J. Adam, 2021, European journal of cancer.

Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

D. Planchard, A. Desnoyer, N. Chaput, 2020, Clinical Cancer Research.

10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient

D. Planchard, J. Soria, T. le Chevalier, 2015, European Respiratory Journal.

Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer

D. Planchard, J. Adam, J. Soria, 2016, Tumori.

1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5).

J. Strausz, F. de Marinis, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5).

F. de Marinis, D. Planchard, M. Schuler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer

D. Planchard, L. Lacroix, B. Besse, 2019, Clinical Cancer Research.

Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

N. Hanna, C. Gridelli, E. Felip, 2017, Clinical lung cancer.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

S. Novello, D. Planchard, M. Hellmann, 2018, Journal of Thoracic Oncology.

Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.

D. Planchard, N. Chaput, F. Barlesi, 2023, European journal of cancer.

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report

D. Planchard, M. Ghigna, C. Le Péchoux, 2022, JTO clinical and research reports.

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].

D. Planchard, J. Soria, B. Besse, 2015, Bulletin du cancer.

Identification of driver mutations in lung cancer: first step in personalized cancer

D. Planchard, 2013, Targeted Oncology.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

D. Planchard, P. Cournède, J. Adam, 2020, European Radiology.

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

D. Planchard, David Planchard, Ivana Sullivan, 2017, Front. Med..

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer

N. Rosenfeld, D. Planchard, V. Plagnol, 2019, JCO precision oncology.

Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation.

D. Planchard, P. Fouret, A. Handra‐Luca, 2009, Oral oncology.

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

D. Planchard, I. Sullivan, 2016, Therapeutic advances in respiratory disease.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Jordi Remon, J. Pignon, D. Planchard, 2017, Lung cancer.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

T. Mok, G. Veronesi, D. Planchard, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

M. Socinski, G. Scagliotti, S. Novello, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.

D. Planchard, N. Chaput, F. André, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

449PDUPDATED SAFETY AND EFFICACY FROM A PHASE I STUDY OF AZD9291 IN PATIENTS (PTS) WITH EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC).

M. Ranson, E. Felip, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

H. Groen, J. Ware, K. Morrissey, 2017, European Journal of Cancer.

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

D. Planchard, C. Caramella, A. Schernberg, 2018, PloS one.

Small-cell lung cancer and large-cell neuroendocrine tumors of the lung

D. Planchard, E. Baudin, 2013 .

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

D. Planchard, C. Caramella, B. Besse, 2019, British Journal of Cancer.

Lung cancer in never-smokers

D. Planchard, B. Besse, 2015, European Respiratory Journal.

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

D. Planchard, J. Soria, C. Bourgier, 2013, Oncology Research and Treatment.

An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

H. Groen, J. Rigas, S. Novello, 2016 .

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

D. Planchard, F. André, J. Soria, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

D. Planchard, F. André, J. Soria, 2016, Clinical Cancer Research.

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer

D. Planchard, P. Abdayem, 2021, European Respiratory Review.

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.

N. Reinmuth, D. Planchard, R. Soo, 2020, Annals of Oncology.

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

D. Planchard, S. Michiels, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

D. Planchard, N. Manaresi, B. Besse, 2021, npj Precision Oncology.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

D. Planchard, J. Soria, C. Lindsay, 2017, Cancer research.

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

D. Planchard, I. Sullivan, 2016, Future oncology.

p38 mitogen‐activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients

D. Planchard, J. Soria, P. Fouret, 2012, Cancer.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

N. Girard, D. Planchard, G. Zalcman, 2015, Expert review of anticancer therapy.

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

N. Girard, D. Planchard, G. Zalcman, 2014, Bulletin du cancer.

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

D. Planchard, F. André, J. Adam, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine, Ifosfamide, and Cisplatin Combination (GIP) in Treatment of Patients With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer: Results of a Phase II Study

D. Planchard, P. Blanc, D. Genet, 2006, American journal of clinical oncology.

Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.

T. Mok, K. Kerr, G. Veronesi, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

D. Planchard, J. Bosch-Barrera, G. Zalcman, 2022, European journal of cancer.

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.

D. Planchard, T. Yap, T. Guren, 2021, The Lancet. Respiratory medicine.

Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.

D. Planchard, N. Viñolas, N. Reguart, 2021, Lung cancer.

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Keunchil Park, D. Planchard, L. Paz-Ares, 2020, Clinical Cancer Research.

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

D. Planchard, P. Saintigny, L. Lacroix, 2020, PloS one.

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.

D. Planchard, V. Plagnol, J. Adam, 2020, JCO precision oncology.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer

D. Planchard, J. Soria, C. Lindsay, 2015, Expert review of molecular diagnostics.

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).

D. Santamaría, S. Novello, D. Planchard, 2021, Cancer treatment reviews.

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer

Roman K. Thomas, D. Planchard, M. Peifer, 2021, npj Precision Oncology.

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

E. Solary, D. Planchard, A. Eggermont, 2020, npj Precision Oncology.

Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer.

D. Planchard, C. Caramella, B. Besse, 2020, Clinical lung cancer.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

J. Mosser, D. Planchard, J. Merlio, 2019, European journal of cancer.

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

D. Planchard, B. Johnson, 2018, Archives of pathology & laboratory medicine.

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

J. Pignon, D. Planchard, J. Adam, 2017, Oncotarget.

D. Planchard, N. Chaput, J. Adam, 2017, Journal of Crohn's & colitis.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

D. Planchard, E. Baudin, M. Schlumberger, 2015, Endocrine-related cancer.

Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.

D. Planchard, N. Chaput, J. Mazières, 2021, Lung cancer.

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

J. Pignon, D. Planchard, J. Soria, 2014, Lung cancer.

Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.

H. Groen, D. Planchard, J. Mazières, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

N. Girard, D. Planchard, T. Ciuleanu, 2022, Journal of Clinical Oncology.

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

D. Planchard, C. Lovly, Helena A. Yu, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

KRAS in NSCLC: State of the Art and Future Perspectives

D. Planchard, N. Normanno, R. Bianco, 2022, Cancers.

MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

H. Popper, D. Planchard, J. Soria, 2010, Clinical Cancer Research.

Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study

D. Planchard, E. Lanoy, M. Bayar, 2017, Supportive Care in Cancer.

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.

D. Planchard, Hugues Talbot, C. Balleyguier, 2020, JAMA oncology.

Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies

D. Planchard, J. Schellens, W. Miller, 2019, Clinical Trials.

Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma

J. Pignon, D. Planchard, J. Soria, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

N. Girard, A. Stenzinger, C. Swanton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

D. Planchard, B. Besse, G. Lopes, 2021, Annals of Oncology.

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

D. Planchard, J. Schellens, W. Miller, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Uncertain benefit from surgery in patients with lung metastases from breast carcinoma

D. Planchard, P. Validire, S. Michiels, 2004, Cancer.

Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).

D. Planchard, J. Adam, J. Soria, 2016 .

Oncogene addiction and immune escape: friends or foes?

D. Planchard, P. Abdayem, 2020, Annals of translational medicine.

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

D. Planchard, C. Caramella, L. Lacroix, 2020 .

A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer.

P. Jänne, D. Planchard, H. Murakami, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors

D. Planchard, O. Mir, A. Paci, 2017, Investigational New Drugs.

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

P. Jänne, D. Planchard, M. Aregay, 2022, Annals of Oncology.

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib

R. Dziadziuszko, D. Planchard, E. Guerini, 2022, ESMO open.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.

Gregory Riely, D. Planchard, M. Hellmann, 2018 .

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

D. Planchard, P. Souquet, F. Bonnetain, 2019, Journal of cachexia, sarcopenia and muscle.

The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma.

D. Planchard, P. Validire, J. Soria, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

D. Planchard, 2020, The New England journal of medicine.

[Pneumoperitoneum and pneumomediastinum complicating non-invasive ventilation].

D. Planchard, J. Meurice, V. Levrat, 2005, Revue des maladies respiratoires.

Reply to N. Singh et al.

D. Planchard, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience

N. Girard, D. Planchard, B. Besse, 2021, Cancers.

[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].

D. Planchard, B. Besse, F. Vaylet, 2011, Revue de pneumologie clinique.

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

D. Planchard, J. Soria, C. Lindsay, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to the letter to the editor 'What is the clinical impact of the LUX-Lung 5 trial?' by Addeo.

D. Planchard, M. Schuler, J. Yang, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of osimertinib in EGFR-mutated non-small cell lung cancer

D. Planchard, L. Mezquita, A. Varga, 2018, Expert opinion on drug safety.

Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC)

D. Planchard, J. Adam, J. Soria, 2016 .

OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

P. Jänne, Ying Cheng, E. Smit, 2021 .

Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study

D. Planchard, S. Michiels, F. André, 2019, Annals of Oncology.

Acquired resistance mechanisms to osimertinib: The constant battle.

D. Planchard, R. Eid, Ziad Zalaquett, 2023, Cancer treatment reviews.

Towards personalized lung cancer CT screening in Europe

J. Borrás, M. Oudkerk, U. Pastorino, 2020 .

1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial

E. Fadel, D. Planchard, J. Adam, 2020 .

LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC

D. Planchard, L. Paz-Ares, P. Dennis, 2017 .

Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)

H. Groen, D. Planchard, J. Mazières, 2017 .

Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.

N. Segata, L. Zitvogel, D. Planchard, 2021 .

Are we reproducible in measurement of NET liver metastasis?

D. Planchard, M. Ducreux, N. Ternès, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

D. Planchard, M. Ducreux, J. Adam, 2017, European journal of cancer.

Outcomes of extended resection for locally advanced thymic malignancies.

E. Fadel, D. Planchard, B. Besse, 2023, Respiratory medicine and research.

OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study

D. Planchard, F. Barlesi, B. Besse, 2018, Journal of Thoracic Oncology.

Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?

D. Planchard, M. Ducreux, E. Baudin, 2019, Neuroendocrinology.

Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance

D. Planchard, Y. Chia, L. Krug, 2022, British journal of clinical pharmacology.

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients.

D. Planchard, S. Michiels, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.

C. Schumann, S. Gettinger, Gregory Riely, 2012 .

Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.

D. Planchard, E. Baudin, A. Italiano, 2023, European journal of cancer.

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

D. Planchard, J. Remon, 2015, Future oncology.

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.

J. Pignon, D. Planchard, N. Chaput, 2019, European journal of cancer.

Abstract 2250: STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance

J. Pignon, D. Planchard, J. Soria, 2016 .

1327PThe Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients

D. Planchard, N. Chaput, J. Adam, 2017 .

FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study

J. Mosser, D. Planchard, J. Merlio, 2021 .

Unexpected cardiotoxicity in HER2-mutant non-small cell lung cancer patients treated with trastuzumab deruxtecan

D. Planchard, A. Azarine, V. Thomas de Montpréville, 2022, JTO Clinical and Research Reports.

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, Annals of Oncology.

MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer.

D. Planchard, J. Soria, R. Pirker, 2009, Journal of Clinical Oncology.

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

D. Planchard, N. Chaput, J. Adam, 2020, Cancers.

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

D. Planchard, S. Michiels, F. André, 2020, JTO clinical and research reports.

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update

D. Planchard, C. Genova, J. Benítez, 2021, Expert opinion on pharmacotherapy.

P1.07-012 Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort: Topic: Drug Treatment Alone and in Combination with Radiotherapy

D. Planchard, O. Molinier, J. Mazières, 2017 .

An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer

D. Planchard, M. Riudavets, 2022, Expert opinion on pharmacotherapy.

Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)

D. Planchard, D. Camidge, K. Goto, 2021, Poster Presentations - Proffered Abstracts.

Cannabis use and lung cancer: time to stop overlooking the problem?

Y. Castier, A. Chapelier, E. Fadel, 2021, European Respiratory Journal.

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.

D. Planchard, C. Caramella, C. Lindsay, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report.

J. Pignon, D. Planchard, J. Soria, 2012 .

Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial.

A. Fourcade, D. Planchard, O. Mir, 2020 .

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

F. Bidault, D. Planchard, J. Soria, 2018, European journal of cancer.

975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

P. Jänne, E. Felip, D. Planchard, 2022, Annals of Oncology.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

N. Rosenfeld, D. Planchard, V. Plagnol, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

J. Thiery, E. Solary, D. Planchard, 2019, Clinical Cancer Research.

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

D. Gandara, D. Planchard, S. Ramalingam, 2014 .

MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer

D. Planchard, J. Mazières, P. Saintigny, 2019, Journal of Thoracic Oncology.

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].

D. Planchard, A. Italiano, J. Soria, 2007, Bulletin du cancer.

An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.

D. Planchard, V. Plagnol, J. Adam, 2018 .

MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01

P. Jänne, E. Smit, E. Felip, 2021 .

Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.

D. Planchard, E. Baudin, V. Hervieu, 2016, Lung cancer.

MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)

D. Planchard, J. Soria, G. Tortora, 2017 .

Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials.

D. Planchard, B. Besse, A. Hollebecque, 2019 .

Durvalumab for the treatment of non-small cell lung cancer

D. Planchard, L. Mezquita, 2018, Expert review of respiratory medicine.

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

J. Strausz, S. Ou, Keunchil Park, 2012 .

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome.

C. Lázaro, G. Capellá, D. Planchard, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P3.02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients: Topic: IT Biomarkers

D. Planchard, N. Chaput, B. Besse, 2017 .

Feasibility of a video-based cognitive behavioral therapy for insomnia in French adult cancer outpatients: results from the Sleep-4-All-1 study

D. Planchard, S. Dauchy, G. Ninot, 2021, Supportive Care in Cancer.

RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.

E. Felip, D. Planchard, V. Ludovini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Three-year overall survival update from the PACIFIC trial

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Annals of Oncology.

MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma

D. Planchard, X. Paoletti, J. Soria, 2019, Journal of Thoracic Oncology.

Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).

D. Planchard, X. Paoletti, J. Soria, 2018 .

1323PBaseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients

D. Planchard, J. Adam, J. Soria, 2017 .

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

D. Planchard, C. Le Péchoux, L. Mezquita, 2019, Therapeutic advances in respiratory disease.

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes.

D. Planchard, A. Dechaphunkul, M. Boyer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Y. Ohe, D. Planchard, A. Dechaphunkul, 2018 .

LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

D. Planchard, C. Faivre-Finn, S. Senan, 2020 .

MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

C. Lefebvre, D. Ruysscher, D. Planchard, 2018, Journal of Thoracic Oncology.

LBA3A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC – UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

P. Jänne, M. Ahn, D. Planchard, 2015 .

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018 .

HLA-A2 and immune checkpoints inhibitors in advanced non-small cell lung cancer (NSCLC) patients

D. Planchard, N. Chaput, J. Adam, 2016 .

Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated

D. Planchard, N. Chaput, J. Adam, 2019 .

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Ongoing progress in BRAF-mutated non-small cell lung cancer.

D. Planchard, P. Abdayem, 2022, Clinical advances in hematology & oncology : H&O.

3025 Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT)

J. Pignon, D. Planchard, J. Adam, 2015 .

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications

D. Planchard, A. Italiano, B. Besse, 2023, The Journal of Liquid Biopsy.

Local control strategies for management of NSCLC with oligoprogressive disease.

D. Planchard, B. Besse, A. Levy, 2023, Cancer treatment reviews.

Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.

D. Planchard, V. Baracos, E. Lanoy, 2022, European journal of cancer.

MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC

D. Planchard, N. Chaput, J. Adam, 2019, Journal of Thoracic Oncology.

Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer

D. Planchard, P. Cournède, Hugues Talbot, 2023, Journal for immunotherapy of cancer.

112PPathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)

D. Planchard, J. Adam, J. Soria, 2017 .

Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)

S. Lantuejoul, D. Planchard, O. Molinier, 2019, Annals of Oncology.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].

D. Planchard, D. Planchard, E. Leprieur, 2011, Revue de pneumologie clinique.

Targeting ALK-rearranged non-small-cell lung cancer: an update.

D. Planchard, I. Sullivan, 2017, Future oncology.

Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial

M. Socinski, G. Scagliotti, N. Pavlakis, 2017 .

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D. Planchard, T. Mok, P. V. Van Schil, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

D. Planchard, F. André, J. Adam, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment.

N. Reinmuth, D. Planchard, R. Soo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study

D. Planchard, B. Besse, P. Garrido, 2016 .

Does perioperative immunotherapy reduce the risk of second primary cancers?

D. Planchard, M. Tagliamento, J. Remon, 2023, European journal of cancer.

Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions.

D. Planchard, B. Besse, A. Gazzah, 2023, JAMA oncology.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Senan, K. Kerr, S. Novello, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Jie Yang, P. Jänne, E. Smit, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACUTE TUBULAR NECROSIS DUE TO RHABDOMYOLYSIS RESULTING FROM INFLUENZA A INFECTION

D. Planchard, M. Paccalin, C. Pradère, 2006, Journal of The American Geriatrics Society.

Durvalumab in non-small-cell lung cancer patients: current developments.

D. Planchard, L. Mezquita, 2018, Future oncology.

D. Planchard, M. Peeters, M. Pegram, 2021, Future Oncology.

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

P. Jänne, D. Planchard, Y. Rukazenkov, 2023, The New England journal of medicine.

Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?

D. Planchard, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NTRK gene fusion testing and management in lung cancer.

A. Drilon, D. Planchard, E. Rudzinski, 2024, Cancer treatment reviews.

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

D. Planchard, J. Rotow, Yi‐Long Wu, 2024, Frontiers in oncology.

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

P. Jänne, B. Chewaskulyong, D. Planchard, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[DNA repair pathways and non-small cell lung cancer: clinical perspectives].

D. Planchard, J. Adam, J. Soria, 2011, Bulletin du cancer.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

D. Planchard, J. Soria, C. Lindsay, 2017, Cancer research.

ASSOCIATION OF LIPI SCORE WITH IMMUNOTHERAPY OUTCOMES IN ELDERLY POPULATION

D. Planchard, B. Besse, A. Hollebecque, 2019, Journal of Geriatric Oncology.